F-18-FDOPA¹⁸F-FDOPA
A dopamine-precursor PET tracer spanning neuroendocrine tumors, parkinsonism, and brain tumors
Quick Answer
F-18-FDOPA is a dopamine-precursor (L-DOPA analog) PET tracer taken up by cells via the large amino-acid transporter (LAT) and decarboxylated by aromatic L-amino-acid decarboxylase (AADC) — so it images tissues with catecholamine/amine-handling capacity. This gives it three distinct roles: neuroendocrine tumors (including catecholamine-secreting pheochromocytoma/paraganglioma, medullary thyroid carcinoma, and congenital hyperinsulinism), presynaptic dopaminergic imaging in parkinsonism, and brain tumors (low normal cortical background → good tumor-to-background). Carbidopa premedication boosts tumor uptake by blocking peripheral decarboxylation.
Mechanism
FDOPA enters cells through the LAT amino-acid transporter and is converted by AADC to F-18-dopamine, which is stored in vesicles — imaging the amine precursor uptake and decarboxylation (APUD) pathway shared by neuroendocrine cells and dopaminergic neurons. In the striatum, uptake reflects presynaptic nigrostriatal dopaminergic terminal integrity; in tumors, it reflects neuroendocrine amine-handling.
Biodistribution
Physiologic uptake in the basal ganglia (striatum), pancreas, duodenum, liver, and biliary/renal excretion; the gallbladder and bowel activity can obscure abdominal lesions. Carbidopa premedication reduces normal pancreatic/renal background and increases tumor uptake (less peripheral decarboxylation of tracer).
Clinical Indications
- Neuroendocrine tumors: pheochromocytoma/paraganglioma (especially SDHx-related and MIBG-negative), medullary thyroid carcinoma recurrence (often the most sensitive localizer), well-differentiated GEP-NETs (complementary to DOTATATE), and carcinoid.
- Congenital hyperinsulinism: distinguishes focal (surgically curable) from diffuse pancreatic disease.
- Parkinsonism: presynaptic dopaminergic loss (complementary to DAT-SPECT).
- Brain tumors: grading, biopsy targeting, and recurrence-vs-treatment-effect (low cortical background).
Preparation & Protocol
- Carbidopa premedication (per protocol) to raise tumor uptake and cut renal/pancreatic background.
- Uptake ~60 min (tumor) or dynamic/early imaging for brain applications; standard PET/CT.
- Withhold interfering dopaminergic drugs for neuro studies per protocol.
Interpretation Highlights
- NET localization: FDOPA is often highly sensitive for MTC and for MIBG-negative pheochromocytoma/paraganglioma.
- Congenital hyperinsulinism: focal intense uptake (curable by focal resection) vs diffuse uptake.
- Parkinsonism: reduced putaminal uptake (posterior-to-anterior gradient) supports nigrostriatal degeneration.
- Brain tumor: uptake above normal cortex flags tumor; helps separate recurrence from radiation change.
Reporting Checklist
- State carbidopa premedication and uptake time.
- For NET, report disease sites and note complementarity with DOTATATE/MIBG.
- For hyperinsulinism, classify focal vs diffuse.
- For neuro, describe striatal (putaminal) uptake pattern.
Common Pitfalls
- Physiologic pancreatic/biliary/bowel uptake obscuring abdominal lesions (carbidopa helps).
- Omitting carbidopa where protocol expects it (lower tumor conspicuity).
- Over-reading normal striatal uptake as brain-tumor activity.
Board Pearls
F-18-FDOPA is a dopamine-precursor (L-DOPA analog) taken up via LAT and decarboxylated by AADC, imaging amine-handling tissue. Three roles: neuroendocrine tumors (MTC recurrence — often the most sensitive; MIBG-negative/SDHx pheochromocytoma-paraganglioma; GEP-NETs complementary to DOTATATE), congenital hyperinsulinism (focal vs diffuse), and presynaptic dopaminergic imaging in parkinsonism. Carbidopa premedication boosts tumor uptake by blocking peripheral decarboxylation.
In congenital hyperinsulinism, FDOPA distinguishes focal disease (surgically curable by focal resection) from diffuse disease — a management-defining call. For pheochromocytoma/paraganglioma, FDOPA is especially useful when MIBG is negative and in SDHx-related tumors.
Physiologic striatal uptake reflects presynaptic dopaminergic terminals (reduced putaminal uptake in Parkinson disease — complementary to DAT-SPECT); low normal cortical background makes FDOPA useful for brain-tumor grading and recurrence-vs-radiation-change. Physiologic pancreatic/biliary/bowel activity is the abdominal pitfall — carbidopa mitigates it.
Related Pages
- Tracers: DOTATATE (SSTR), MIBG (catecholamine); diseases: Medullary thyroid carcinoma, Neuroendocrine tumors, Neuroblastoma, Adrenal/pheochromocytoma.
Figure / Diagram Suggestions
- A LAT uptake → AADC decarboxylation mechanism cartoon (carbidopa effect).
- A focal vs diffuse congenital-hyperinsulinism teaching pair.
- A putaminal-gradient parkinsonism illustration.
Self-Check
Q1. By what mechanism does FDOPA accumulate in neuroendocrine and dopaminergic cells?
Answer: Uptake via the large amino-acid transporter (LAT) then decarboxylation by AADC to F-18-dopamine (the amine-precursor-uptake pathway).
Q2. Why is carbidopa given before an FDOPA tumor study?
Answer: It blocks peripheral decarboxylation, increasing tumor uptake and reducing physiologic pancreatic/renal background.
Q3. What management-defining distinction does FDOPA make in congenital hyperinsulinism?
Answer: Focal (surgically curable by focal resection) versus diffuse pancreatic disease.
Q4. When is FDOPA particularly valuable for pheochromocytoma/paraganglioma?
Answer: When MIBG is negative and in SDHx-related tumors — FDOPA is often highly sensitive there.
Evidence & sources
https://nuc.med/fdopa/ Report an issue